PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21925926-0 2012 Secretion of IL-6 and IL-8 from lysophosphatidic acid-stimulated oral squamous cell carcinoma promotes osteoclastogenesis and bone resorption. lysophosphatidic acid 32-53 interleukin 6 Homo sapiens 13-17 21925926-13 2012 Taken together, LPA may be a potent inducer of osteolytic factor IL-6 and IL-8 in OSCC. lysophosphatidic acid 16-19 interleukin 6 Homo sapiens 65-69 21925926-6 2012 LPA induced the secretion of IL-6 and IL-8 in oral squamous cell carcinoma (OSCC). lysophosphatidic acid 0-3 interleukin 6 Homo sapiens 29-33 21925926-14 2012 LPA-induced IL-6 and IL-8 exerted propound effects on RANKL expression in osteoblast and thereby promoted osteoclast formation from osteoclast precursors. lysophosphatidic acid 0-3 interleukin 6 Homo sapiens 12-16 21925926-7 2012 LPA-stimulated secretion of IL-6 and IL-8 is partly dependent on the LPA and EGF receptor (EGFR) pathways. lysophosphatidic acid 0-3 interleukin 6 Homo sapiens 28-32 21925926-8 2012 ERK1/2 and Akt-mediated NF-kappaB and AP-1 were responsible for the LPA-induced IL-6 and IL-8 secretion. lysophosphatidic acid 68-71 interleukin 6 Homo sapiens 80-84 21925926-10 2012 Neutralization against both human IL-6 and IL-8 suppressed osteoclast formation induced by CM derived from the LPA-stimulated OSCC. lysophosphatidic acid 111-114 interleukin 6 Homo sapiens 34-38 21925926-11 2012 Direct treatment with recombinant IL-6 (rIL-6) and/or soluble IL-6 receptor (sIL-6R), or IL-8 (rIL-8) reproduced the effect of the CM derived from the LPA-stimulated OSCC on osteoclast formation. lysophosphatidic acid 151-154 interleukin 6 Homo sapiens 34-38 17253943-7 2006 Co-incubation with LPA attenuated the LPS-induced production of IL-6, without significantly affecting IL-10 secretion or the ability of DC to promote T cell proliferation. lysophosphatidic acid 19-22 interleukin 6 Homo sapiens 64-68 20044439-0 2010 LPA induces IL-6 secretion from aortic smooth muscle cells via an LPA1-regulated, PKC-dependent, and p38alpha-mediated pathway. lysophosphatidic acid 0-3 interleukin 6 Homo sapiens 12-16 20044439-3 2010 To profile LPA-induced cytokine production in vascular smooth muscle cells (SMCs), we used a cytokine antibody array system and found that LPA prominently induces the secretion of IL-6 and monocyte chemoattractant protein (MCP)-1 from human aortic SMCs (HASMCs). lysophosphatidic acid 11-14 interleukin 6 Homo sapiens 180-184 20044439-6 2010 The present study reveals that LPA induces the expression of IL-6 mRNA and protein in HASMCs as well as the secretion of IL-6 protein in a time-dependent manner. lysophosphatidic acid 31-34 interleukin 6 Homo sapiens 61-65 20044439-6 2010 The present study reveals that LPA induces the expression of IL-6 mRNA and protein in HASMCs as well as the secretion of IL-6 protein in a time-dependent manner. lysophosphatidic acid 31-34 interleukin 6 Homo sapiens 121-125 20044439-7 2010 Our results demonstrate that LPA-specific receptor 1 (LPA(1)) mediates LPA-induced IL-6 secretion and that LPA induction of IL-6 is independent of the EGF receptor pathway. lysophosphatidic acid 29-32 interleukin 6 Homo sapiens 83-87 20044439-7 2010 Our results demonstrate that LPA-specific receptor 1 (LPA(1)) mediates LPA-induced IL-6 secretion and that LPA induction of IL-6 is independent of the EGF receptor pathway. lysophosphatidic acid 54-57 interleukin 6 Homo sapiens 83-87 20044439-9 2010 Finally, small interfering RNA depletion experiments revealed that p38alpha is specifically responsible for the LPA-induced IL-6 secretion. lysophosphatidic acid 112-115 interleukin 6 Homo sapiens 124-128 20044439-10 2010 The present study profiles the regulatory relationship between LPA and multiple cytokines in vascular SMCs for the first time, provides the first evidence that LPA upregulates IL-6 in vascular SMCs, and reveals the regulatory mechanism of LPA-induced IL-6 production in HASMCs. lysophosphatidic acid 63-66 interleukin 6 Homo sapiens 176-180 20044439-10 2010 The present study profiles the regulatory relationship between LPA and multiple cytokines in vascular SMCs for the first time, provides the first evidence that LPA upregulates IL-6 in vascular SMCs, and reveals the regulatory mechanism of LPA-induced IL-6 production in HASMCs. lysophosphatidic acid 63-66 interleukin 6 Homo sapiens 251-255 20044439-10 2010 The present study profiles the regulatory relationship between LPA and multiple cytokines in vascular SMCs for the first time, provides the first evidence that LPA upregulates IL-6 in vascular SMCs, and reveals the regulatory mechanism of LPA-induced IL-6 production in HASMCs. lysophosphatidic acid 160-163 interleukin 6 Homo sapiens 176-180 20044439-10 2010 The present study profiles the regulatory relationship between LPA and multiple cytokines in vascular SMCs for the first time, provides the first evidence that LPA upregulates IL-6 in vascular SMCs, and reveals the regulatory mechanism of LPA-induced IL-6 production in HASMCs. lysophosphatidic acid 160-163 interleukin 6 Homo sapiens 251-255 20044439-10 2010 The present study profiles the regulatory relationship between LPA and multiple cytokines in vascular SMCs for the first time, provides the first evidence that LPA upregulates IL-6 in vascular SMCs, and reveals the regulatory mechanism of LPA-induced IL-6 production in HASMCs. lysophosphatidic acid 160-163 interleukin 6 Homo sapiens 176-180 20044439-10 2010 The present study profiles the regulatory relationship between LPA and multiple cytokines in vascular SMCs for the first time, provides the first evidence that LPA upregulates IL-6 in vascular SMCs, and reveals the regulatory mechanism of LPA-induced IL-6 production in HASMCs. lysophosphatidic acid 160-163 interleukin 6 Homo sapiens 251-255 19647363-7 2010 Treatment of the cells with curcumin inhibited LPA-induced IL-6 and IL-8 secretion and STAT3 phosphorylation, leading to blocked ovarian cancer cell motility. lysophosphatidic acid 47-50 interleukin 6 Homo sapiens 59-63 18006645-5 2008 Moreover, exogenously applied LPA induces FLS migration and secretion of IL-8/IL-6, whereas the LPA(3) agonist l-sn-1-O-oleoyl-2-methyl-glyceryl-3-phosphothionate (2S-OMPT) stimulates cytokine synthesis but not cell motility. lysophosphatidic acid 30-33 interleukin 6 Homo sapiens 78-82 17325741-6 2007 Our results strongly suggest that SPARC exerts a dual inhibitory effect on LPA-induced mesothelial-ovarian cancer cell crosstalk through the regulation of both LPA-induced IL-6 production and function. lysophosphatidic acid 75-78 interleukin 6 Homo sapiens 172-176 17325741-6 2007 Our results strongly suggest that SPARC exerts a dual inhibitory effect on LPA-induced mesothelial-ovarian cancer cell crosstalk through the regulation of both LPA-induced IL-6 production and function. lysophosphatidic acid 160-163 interleukin 6 Homo sapiens 172-176 17915188-0 2008 Lysophosphatidic acid-stimulated interleukin-6 and -8 synthesis through LPA1 receptors on human osteoblasts. lysophosphatidic acid 0-21 interleukin 6 Homo sapiens 33-53 17915188-4 2008 The expression of IL-6 and IL-8 mRNAs was maximal at 1-3h, and the increase in IL-6 and IL-8 synthesis in response to lysophosphatidic acid (1-10 microM) occurred in a concentration-dependent manner. lysophosphatidic acid 118-139 interleukin 6 Homo sapiens 18-22 17915188-4 2008 The expression of IL-6 and IL-8 mRNAs was maximal at 1-3h, and the increase in IL-6 and IL-8 synthesis in response to lysophosphatidic acid (1-10 microM) occurred in a concentration-dependent manner. lysophosphatidic acid 118-139 interleukin 6 Homo sapiens 79-83 17915188-7 2008 The pretreatment of SaM-1 cells with U-73122, a phospholipase C (PLC) inhibitor, and 2-APB also inhibited the increase in IL-6 and IL-8 synthesis in response to LPA. lysophosphatidic acid 161-164 interleukin 6 Homo sapiens 122-126 17915188-8 2008 These findings suggest that extracellular LPA-induced IL-6 and IL-8 synthesis occurred through Edg-2 (LPA(1) receptor) and the activation of PLC and IP(3)-mediated intracellular calcium release in SaM-1 cells. lysophosphatidic acid 42-45 interleukin 6 Homo sapiens 54-58 18171700-8 2008 The effects of LPA on the expression of IL-6, IL-8, and vascular endothelial growth factor were examined. lysophosphatidic acid 15-18 interleukin 6 Homo sapiens 40-44 18171700-14 2008 LPA induced IL-8 and IL-6 through different pathways. lysophosphatidic acid 0-3 interleukin 6 Homo sapiens 21-25 18171700-15 2008 LPA-induced IL-8 and IL-6 increased permeability of human umbilical vein endothelial cell monolayer. lysophosphatidic acid 0-3 interleukin 6 Homo sapiens 21-25 18171700-16 2008 CONCLUSIONS: LPA induces IL-8 and IL-6 expressions through LPA receptors and nuclear factor-kappaB dependent pathways in granulosa-lutein cells. lysophosphatidic acid 13-16 interleukin 6 Homo sapiens 34-38 18171700-18 2008 Large amounts of LPA-induced IL-8 and IL-6 from multiple corpora luteae of stimulated ovaries may be one of the pathophysiological causes of ovarian hyperstimulation syndrome. lysophosphatidic acid 17-20 interleukin 6 Homo sapiens 38-42 15471896-0 2005 Up-regulation of interleukin-6 in human ovarian cancer cell via a Gi/PI3K-Akt/NF-kappaB pathway by lysophosphatidic acid, an ovarian cancer-activating factor. lysophosphatidic acid 99-120 interleukin 6 Homo sapiens 17-30 15471896-4 2005 To elucidate the pathogenesis of ovarian cancer, this study investigated how LPA affects IL-6 production in ovarian cancer cells. lysophosphatidic acid 77-80 interleukin 6 Homo sapiens 89-93 15471896-5 2005 Experimental results indicated that LPA stimulates IL-6 expression in all ovarian cancer cell lines tested, but not in normal ovarian surface epithelial (NOSE) cells, owing to the lack of LPA-specific Edg4 and/or Edg7 receptors in NOSE cells. lysophosphatidic acid 36-39 interleukin 6 Homo sapiens 51-55 15471896-6 2005 This work demonstrated that LPA transcriptionally activates IL-6 expression, which can be totally blocked by the pertussis toxin, indicating that Gi-mediated signaling is critically involved in inducing IL-6 by LPA. lysophosphatidic acid 28-31 interleukin 6 Homo sapiens 60-64 15471896-6 2005 This work demonstrated that LPA transcriptionally activates IL-6 expression, which can be totally blocked by the pertussis toxin, indicating that Gi-mediated signaling is critically involved in inducing IL-6 by LPA. lysophosphatidic acid 28-31 interleukin 6 Homo sapiens 203-207 15471896-7 2005 Pharmacological and genetic inhibition assays revealed that Gi-mediated PI3K activation phosphorylated downstream Akt and subsequently induced NF-kappaB activation causes the induction of IL-6 by LPA in SK-OV-3 cells. lysophosphatidic acid 196-199 interleukin 6 Homo sapiens 188-192 15471896-8 2005 In summary, data presented here demonstrate that LPA is an important inducer of IL-6 and LPA-regulated IL-6 expression via a Gi/PI3K-Akt/NF-kappaB pathway in ovarian cancer cells, providing molecular therapeutic targets for treating ovarian cancer. lysophosphatidic acid 49-52 interleukin 6 Homo sapiens 80-84 15471896-8 2005 In summary, data presented here demonstrate that LPA is an important inducer of IL-6 and LPA-regulated IL-6 expression via a Gi/PI3K-Akt/NF-kappaB pathway in ovarian cancer cells, providing molecular therapeutic targets for treating ovarian cancer. lysophosphatidic acid 49-52 interleukin 6 Homo sapiens 103-107 15471896-8 2005 In summary, data presented here demonstrate that LPA is an important inducer of IL-6 and LPA-regulated IL-6 expression via a Gi/PI3K-Akt/NF-kappaB pathway in ovarian cancer cells, providing molecular therapeutic targets for treating ovarian cancer. lysophosphatidic acid 89-92 interleukin 6 Homo sapiens 103-107 15024019-9 2004 Antibody neutralization experiments reveal that IL-6 is responsible for the LPA-induced mitogenic signaling and growth of the LNCaP cells. lysophosphatidic acid 76-79 interleukin 6 Homo sapiens 48-52 15024019-0 2004 Interleukin 6 mediates the lysophosphatidic acid-regulated cross-talk between stromal and epithelial prostate cancer cells. lysophosphatidic acid 27-48 interleukin 6 Homo sapiens 0-13 15041999-8 2004 Pretreatment of the ovarian cancer cells with the pertussis toxin completely inhibited lysophosphatidic acid-stimulated production of interleukin-6, interleukin-8 and tumor necrosis factor-alpha. lysophosphatidic acid 87-108 interleukin 6 Homo sapiens 134-147 15024019-8 2004 Protein analysis demonstrates that treatment of the PS30 cells with LPA induces synthesis of interleukin 6 (IL-6). lysophosphatidic acid 68-71 interleukin 6 Homo sapiens 93-106 15024019-8 2004 Protein analysis demonstrates that treatment of the PS30 cells with LPA induces synthesis of interleukin 6 (IL-6). lysophosphatidic acid 68-71 interleukin 6 Homo sapiens 108-112 14670967-2 2004 In the current study, we demonstrated that LPA is a potent inducer of interleukin-6 (IL-6) and interleukin-8 (IL-8) production in ovarian cancer cells. lysophosphatidic acid 43-46 interleukin 6 Homo sapiens 70-83 14670967-2 2004 In the current study, we demonstrated that LPA is a potent inducer of interleukin-6 (IL-6) and interleukin-8 (IL-8) production in ovarian cancer cells. lysophosphatidic acid 43-46 interleukin 6 Homo sapiens 85-89 14670967-8 2004 Further, the effect of LPA on IL-6 and IL-8 generation is mediated by the Edg LPA receptors as enforced expression of LPA receptors restored LPA-induced IL-6 and IL-8 production in non-responsive cells and enhanced the sensitivity to LPA in responsive cell lines. lysophosphatidic acid 23-26 interleukin 6 Homo sapiens 30-34 14670967-8 2004 Further, the effect of LPA on IL-6 and IL-8 generation is mediated by the Edg LPA receptors as enforced expression of LPA receptors restored LPA-induced IL-6 and IL-8 production in non-responsive cells and enhanced the sensitivity to LPA in responsive cell lines. lysophosphatidic acid 23-26 interleukin 6 Homo sapiens 153-157 14670967-8 2004 Further, the effect of LPA on IL-6 and IL-8 generation is mediated by the Edg LPA receptors as enforced expression of LPA receptors restored LPA-induced IL-6 and IL-8 production in non-responsive cells and enhanced the sensitivity to LPA in responsive cell lines. lysophosphatidic acid 78-81 interleukin 6 Homo sapiens 30-34 14670967-8 2004 Further, the effect of LPA on IL-6 and IL-8 generation is mediated by the Edg LPA receptors as enforced expression of LPA receptors restored LPA-induced IL-6 and IL-8 production in non-responsive cells and enhanced the sensitivity to LPA in responsive cell lines. lysophosphatidic acid 78-81 interleukin 6 Homo sapiens 153-157 14670967-8 2004 Further, the effect of LPA on IL-6 and IL-8 generation is mediated by the Edg LPA receptors as enforced expression of LPA receptors restored LPA-induced IL-6 and IL-8 production in non-responsive cells and enhanced the sensitivity to LPA in responsive cell lines. lysophosphatidic acid 78-81 interleukin 6 Homo sapiens 30-34 14670967-8 2004 Further, the effect of LPA on IL-6 and IL-8 generation is mediated by the Edg LPA receptors as enforced expression of LPA receptors restored LPA-induced IL-6 and IL-8 production in non-responsive cells and enhanced the sensitivity to LPA in responsive cell lines. lysophosphatidic acid 78-81 interleukin 6 Homo sapiens 153-157 14670967-10 2004 These studies elucidate the transcriptional mechanism and the Edg LPA receptors involved in LPA-induced IL-6 and IL-8 production and suggest potential strategies to restrain the expression of these cytokines in ovarian cancer. lysophosphatidic acid 66-69 interleukin 6 Homo sapiens 104-108 35365723-6 2022 IL-8, IL-6 and TNF-alpha secretion was induced by LPA in MDA-MB-468 cells. lysophosphatidic acid 50-53 interleukin 6 Homo sapiens 6-10 30362520-8 2019 Soluble factors derived from cyclooxygenase-2 and IL-6 pathways were involved in H8-EA.hy926 interaction under the LPA effect. lysophosphatidic acid 115-118 interleukin 6 Homo sapiens 50-54 32179099-6 2020 LPA was found to prevent survival of Sa3, a human gingival epithelium-derived tumor cell line, activate Sa3 through Ca2+ mobilization, and release interleukin 6 from Sa3 in vitro. lysophosphatidic acid 0-3 interleukin 6 Homo sapiens 147-160 30362520-9 2019 Moreover, LPA increased the levels of IL-6 mRNA by cyclooxygenase-2 pathway in H8 cells. lysophosphatidic acid 10-13 interleukin 6 Homo sapiens 38-42 27390295-4 2016 We used dermal fibroblasts from SSc patients and control subjects to evaluate LPA-induced expression of IL-6, and IL-6-induced expression of ATX. lysophosphatidic acid 78-81 interleukin 6 Homo sapiens 104-108 29209219-12 2017 In TNFalpha-primed RAFLS the super-production of IL-8 and IL-6 induced by LPA occurs mainly via MSK-independent pathways, and simultaneous inhibition of at least two MAPK signaling pathways was required to block their synthesis. lysophosphatidic acid 74-77 interleukin 6 Homo sapiens 58-62 29209219-13 2017 Since simultaneous inhibition of both the p38MAPK and ERK-MSK-CREB pathways are required to significantly reduce LPA-mediated IL-8 and IL-6 production in TNFalpha-preconditioned RAFLS, drug combinations targeting these two pathways are potential new strategies to treat rheumatoid arthritis. lysophosphatidic acid 113-116 interleukin 6 Homo sapiens 135-139 27390295-10 2016 Expression of both ATX and IL-6 was increased in SSc skin, and LPA-induced IL-6 levels and IL-6-induced ATX levels were increased in fibroblasts from SSc patients compared with controls. lysophosphatidic acid 63-66 interleukin 6 Homo sapiens 75-79 27390295-10 2016 Expression of both ATX and IL-6 was increased in SSc skin, and LPA-induced IL-6 levels and IL-6-induced ATX levels were increased in fibroblasts from SSc patients compared with controls. lysophosphatidic acid 63-66 interleukin 6 Homo sapiens 75-79 26553339-5 2015 In hypoxia and serum-deprived culture conditions, LPA induces CD34(+) cell proliferation without maintaining the their undifferentiating state, and enhances IL-8, IL-6 and G-CSF secretion during the first 12 h compared to non-treated cells. lysophosphatidic acid 50-53 interleukin 6 Homo sapiens 163-167 27680872-9 2016 Furthermore, the expression of IL-6 and IL-8 increased in LPA-stimulated human primary granulosa cells (P < .01). lysophosphatidic acid 58-61 interleukin 6 Homo sapiens 31-35 27680872-10 2016 Co-stimulation with rPEDF decreased the expression of LPA-induced IL-6 and IL-8 mRNA and protein by 4- and 2- to 5-fold, respectively. lysophosphatidic acid 54-57 interleukin 6 Homo sapiens 66-70 24792438-1 2014 Lysophosphatidic acid (LPA) is a pleiotropic lipid mediator that promotes motility, survival, and the synthesis of chemokines/cytokines such as interleukin-8 (IL-8) and interleukin-6 by human fibroblast-like synoviocytes from patients with rheumatoid arthritis (RAFLS). lysophosphatidic acid 0-21 interleukin 6 Homo sapiens 169-182 24792438-1 2014 Lysophosphatidic acid (LPA) is a pleiotropic lipid mediator that promotes motility, survival, and the synthesis of chemokines/cytokines such as interleukin-8 (IL-8) and interleukin-6 by human fibroblast-like synoviocytes from patients with rheumatoid arthritis (RAFLS). lysophosphatidic acid 23-26 interleukin 6 Homo sapiens 169-182